M&T Bank Corp raised its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 100.0% during the 4th quarter ...

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...

In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands against the other up and coming stocks. Donald Trump's victory in the recent presidential ...

NASDAQ:GPCR opened at $20.53 on Wednesday. The stock has a 50-day simple moving average of $25.72 and a two-hundred day simple moving average of $32.74. Structure Therapeutics has a 52-week low of ...

Heptares was founded in 2007 on this technology, and Nxera is building on this long history and experience to develop the next generation of GPCR-targeted drugs — and beyond. With more than 800 ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) today and ...

In trading on Wednesday, shares of Structure Therapeutics Inc (Symbol: GPCR) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $19.61 per share.

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of weight loss drug developers gained on Wednesday after Roche (OTCQX:RHHBF) announced a multi-billion-dollar deal ...